Table 1 Demographic and clinical data, lupus activity (SLEDAI) and individual therapy of the patients at the time of analysis
Patient ID | Sex | Age, y | B cells/μL blood | anti-dsDNA IgG, U/mL | SLEDAI | Treatment | Prednisolone dose, mg/d |
|---|---|---|---|---|---|---|---|
SLE1 | F | 61 | 187 | 0 | 7 | Pred | 5.0 |
SLE2 | F | 31 | 320 | 0 | 5 | Pred, MTX | 5.0 |
SLE3 | F | 30 | 159 | 0 | 4 | Pred, MMF | 5.0 |
SLE4 | F | 25 | 132 | 45 | 8 | Pred, Aza, HCQ | 5.0 |
SLE5 | F | 36 | 216 | 38 | 8 | Pred, Aza | 7.5 |
SLE6 | F | 39 | 538 | 50 | 6 | Pred, MMF | 5.0 |
SLE7 | F | 22 | 164 | 0 | 4 | Pred | 5.0 |
SLE8 | F | 44 | 108 | 0 | 5 | HCQ | 0 |
SLE9 | F | 48 | 67 | 75 | 8 | Pred, MMF | 5.0 |
SLE10 | M | 20 | 89 | 50 | 10 | Pred, Aza | 5.0 |
SLE11 | F | 30 | 305 | 45 | 6 | Pred | 5.0 |
SLE12 | F | 33 | 468 | 0 | 5 | Pred | 8.0 |
SLE13 | F | 23 | 785 | 125 | 14 | Pred, HCQ | 100.0 |
SLE14 | F | 33 | 110 | 18 | 4 | Pred, HCQ | 5.0 |
SLE15 | F | 32 | 75 | 60 | 12 | Pred, MMF | 8.0 |
SLE16 | F | 37 | ND | 2,000 | 15 | Pred, HCQ | 25.0 |
SLE17 | F | 38 | 192 | 21 | 8 | Pred, HCQ, MMF | 7.5 |
SLE18 | F | 47 | 114 | 1,400 | 14 | Therapy naive | 0 |
SLE19 | F | 59 | 26 | 0 | 5 | Pred, Aza | 5.0 |
SLE20 | F | 30 | 32 | 1,000 | 5 | HCQ | 0 |
SLE21 | F | 51 | 81 | 200 | 6 | Pred, Aza | 7.5 |
SLE22 | F | 28 | 56 | 0 | 6 | Ciclosporine, Pred | 5.0 |
SLE23 | F | 33 | 98 | 0 | 6 | Pred, Aza | 5.0 |
SLE24 | F | 32 | 155 | 17.5 | 18 | Cylophosphamide, Pred | 7.5 |
SLE25 | F | 29 | 19 | positive | 7 | Ciclosporine, Pred | - |
SLE26 | M | 21 | 79 | positive | 6 | Pred, MMF | - |
SLE27 | F | 37 | 118 | positive | 5 | Pred, Aza | - |
SLE28 | F | 74 | 20 | negative | 5 | Antimalarials | - |
SLE29 | F | 35 | 75 | positive | 6 | Pred, Antimalarials | - |
SLE30 | F | 33 | 35 | positive | 7 | Pred, MMF | - |